NCT02442531View on ClinicalTrials.gov

A Study of CriPec® Docetaxel Given to Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
CancerMetastatic CancerSolid Tumors
Interventions
DRUG

CriPec® docetaxel

-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops

Trial Locations (4)

Unknown

University Hospital Leuven, Leuven

VUMC Amsterdam, Amsterdam

UMC Groningen, Groningen

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Cristal Therapeutics

INDUSTRY